Hims & Hers Stock Jumps. A Generic Version of Novo Nordisk Diabetes Drug Is Close.
Telehealth company Hims & Hers said late Monday in an earnings update that it plans to launch a generic version of Novo ...
Hims & Hers shares rally on results, but execs say GLP-1 drug shortage ‘is not abating’
Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...
Seeking Alpha10h
Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow
Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong ...
Hims & Hers Health jumps on earnings. CFO talks GLP-1 influences.
Hims & Hers Health (HIMS) shares jumped in extended trading after the company reported better than expected third quarter ...
Modern Healthcare5h
Hims & Hers defends compounded GLP-1s as shortages wane
Compounded GLP-1s are essentially copies of popular weight loss medications made by manufacturers such as Novo Nordisk and Eli Lilly. Hims & Hers CEO Andrew Dudum said during the company's third ...
Hims & Hers reports Q3 EPS 32c, consensus 4c
Reports Q3 revenue $401.6M, consensus $382.2M. “Improving momentum in both the Hims and Hers brands delivered another strong quarter of ...
Palantir, Trump Media, Hims & Hers Health, NXP Semiconductors, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
The U.S. stock market experienced a slight downturn on Monday, with the S&P 500 index dipping approximately 0.3%. The Dow ...
Hims & Hers Health plans to offer generic version of Novo Nordisk's drug
Hims & Hers currently offers compounded GLP-1 weight-loss injections at $199 per month and weight management oral medication ...
uk.investing.com on MSN3h
Hims & Hers Health shares spike after group posts earnings beat, raises guidance
Hims & Hers Health (NYSE:HIMS) reported third-quarter earnings that surpassed analyst expectations and raised its full-year ...